4 ms·
„In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of
by 2-718-281-828 4y ago
„In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells.“
via https://nitter.net/Tim_Roehn/status/1619281947741806592#m https://nitter.net/Tim_Roehn/status/1619281947741806592#m
so they practice gain of function.
and i bet they don't do that in the us. wasn't there some interesting back and forth about ominous us led bio engineering labs in the ukraine? someone with a link to that senate hearing with rand paul iirc. </TFH>
- unlikelymordant 4y ago"It is important to note that these studies are required by U.S. and global regulators for all antiviral products" - i think this bit of the paragraph you highlighted changes the meaning somewhat.
- tonetheman 4y agoExactly this. It is laughable that the conservatives/Republicans/Fascists of my country (US) are all against evil X. And they literally do not understand what evil X is. But they are indeed against it. It is hard to see what the end game of this nonsense. I am sure there is an ending part to it but so far it is just dummies saying gain of function over and over hoping it sticks.
- ren_engineer 4y agobig pharma definitely isn't known for handing large sums of money to regulators and outright creating many regulations to entrench themselves and creating a moat for startups. These multi-billion dollar multinational corporations having nothing but the publics best interest at heart and don't care about profit at all
- nhchris 4y agoIn addition to the fact that pharma tends to write their own regulations, as ren_engineer pointed out, it's ambiguous what "these studies" refers to. It could refer only to the "in vitro resistance selection experiments" mentioned, and not require gain-of-function engineering - a requirement I would find highly surprising.